CorMedix (CRMD) said Monday that its large dialysis organization customer has begun ordering and will start implementing DefenCath in H2 2025, targeting at least 50% more patients than previously planned.
The company said it had amended its agreement with the organization to reflect this broader rollout, which is expected to contribute modestly to June revenue and drive stronger growth in the second half of the year.
Due to the expanded implementation, CorMedix has raised its Q2 net sales guidance to a range of $35 million to $40 million from $31 million.
Shares of the company were up 15.5% in Monday's premarket activity.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。